BOLTHIGH SIGNALFINANCIAL10-K

BOLT shows dramatic balance sheet contraction with total assets declining 43% and stockholders equity falling 54%, despite improved operating performance and cash position.

The massive decline in stockholders equity alongside total asset reduction suggests significant dilution or write-downs occurred during this period, which is concerning for existing shareholders despite operational improvements. While the company improved its cash burn rate and operating losses, the balance sheet deterioration indicates potential financial restructuring or significant impairments that warrant close investor scrutiny.

Comparing 2026-03-12 vs 2025-03-24View on EDGAR →
FINANCIAL ANALYSIS

BOLT's financial picture presents a mixed but concerning narrative - while operational metrics improved significantly with R&D expenses cut in half (-50.4%) and operating losses reduced by 51%, the balance sheet contracted dramatically with total assets falling 43% and stockholders equity declining 54%. Despite cash and equivalents increasing 62% to $11.7M and current liabilities decreasing 47%, the massive equity decline suggests significant dilution or asset write-downs occurred. The overall picture signals a company that has improved its burn rate and operational efficiency but at the cost of substantial shareholder value destruction.

FINANCIAL STATEMENT CHANGES
Capital Expenditure
Cash Flow
+75.6%
$41K$72K

Capital expenditure jumped 75.6% — major investment cycle underway; assess returns on deployment.

Cash & Equivalents
Balance Sheet
+62.4%
$7.2M$11.7M

Cash position surged 62.4% — strong cash generation or capital raise providing significant financial cushion.

Stockholders Equity
Balance Sheet
-53.7%
$57.2M$26.5M

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

Operating Income
P&L
+50.6%
-$73.0M-$36.1M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

R&D Expense
P&L
-50.4%
$57.5M$28.5M

R&D spending cut 50.4% — could signal cost discipline or concerning reduction in innovation investment.

Net Income
P&L
+47.1%
-$63.1M-$33.4M

Net income grew 47.1% — bottom-line growth signals improving overall business health.

Current Liabilities
Balance Sheet
-46.8%
$15.9M$8.4M

Current liabilities reduced — improved short-term financial position and working capital health.

Total Assets
Balance Sheet
-43%
$99.6M$56.7M

Total assets contracted 43% — asset sales, write-downs, or balance sheet optimization underway.

Current Assets
Balance Sheet
-40.4%
$50.8M$30.3M

Current assets declined 40.4% — monitor working capital adequacy and short-term liquidity.

Operating Cash Flow
Cash Flow
+35%
-$61.3M-$39.9M

Operating cash flow surged 35% — exceptional cash generation, highest quality earnings signal.

LANGUAGE CHANGES
NEW — 2026-03-12
PRIOR — 2025-03-24
ADDED
As of March 6, 2026, the Registrant had 1,921,567 shares of common stock outstanding.
) and other jurisdiction; our ability to obtain funding for our operations, including funding necessary to complete further development and any commercialization of our product candidates; and regulatory developments in the U.S.
In addition, statements that we believe and similar statements reflect our beliefs and opinions on the relevant subject.
These statements are based upon information available to us as of the date of this Annual Report on Form 10-K, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information.
These statements are inherently uncertain, and investors are cautioned not to unduly rely upon these statements.
+7 more — sign up free →
REMOVED
Overview We are a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer.
Our product candidates use pattern recognition receptors in the innate immune system to help the body recognize tumor cells for a productive anti-cancer response.
Our proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads.
We believe that ISACs have the potential to transform the cancer treatment landscape in a way similar to what we ve seen with antibody-drug conjugates, or ADCs.
Many antibodies that target tumor antigens could be made into ISACs, providing us with future opportunities.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →